Boardroom Shuffle: Mahamaya Lifesciences Appoints Amarendra Mohapatra as CFO

Mahamaya Lifesciences appoints Amarendra Mohapatra as CFO as Prashant Krishnamurthy transitions to Managing Director.

Executive Summary

Mahamaya Lifesciences Limited announced a major executive leadership reshuffle via official stock exchange filings in August 2026. Effective November 1, 2026, Amarendra Mohapatra will take over as Chief Financial Officer (CFO), succeeding Prashant Krishnamurthy. Krishnamurthy, who previously held the dual role of Executive Director and CFO, has been re-designated as the company's Managing Director.

Executive Board and Key Managerial Personnel Restructuring

NEW DELHI — In a strategic governance transition aimed at strengthening its administrative framework, Mahamaya Lifesciences has formalized key changes among its Key Managerial Personnel (KMP). According to corporate disclosures submitted to the BSE Limited SME platform, the board approved the transition to optimize leadership oversight across its expanding agricultural crop protection and chemical manufacturing operations.

Under the revised leadership schedule, Prashant Krishnamurthy will step down from his current CFO responsibilities effective close of business on October 31, 2026, stepping directly into the role of Managing Director starting November 1, 2026. Concurrently, incoming finance executive Amarendra Mohapatra has been appointed as the new CFO, effective November 1, 2026, to oversee fiscal compliance, financial planning, and corporate accounting controls. Additionally, previous leadership transitions include Krishnamurthy Ganesan transitioning to the role of Chairman.

Strategic Implications for Investors and Stakeholders

The executive re-designation aligns with the company's upcoming corporate milestones, including its scheduled annual general meeting framework and governance updates for fiscal 2027. Market analysts note that clear management succession and dedicated financial leadership are vital for maintaining robust operational transparency, regulatory compliance, and investor confidence in specialized agrochemical enterprises.

Mahamaya Lifesciences continues to focus on expanding its domestic and export market footprint in crop protection, plant nutrition, and household pesticide solutions. The structured segregation of executive management and financial controllership is expected to enhance internal governance controls as the company scales its commercial operations.

Official Sources Section

Information regarding these corporate governance updates and management changes is sourced directly from regulatory filings and announcements published on the BSE Limited corporate portal and archived via Mahamaya Lifesciences Investor Relations. Supplementary market tracking data is available through Trendlyne Financial Analytics.

Quote Section

"According to officials, the board-approved leadership transition is designed to reinforce corporate governance and align executive bandwidth with the company's long-term strategic growth objectives."

Why It Matters

For investors and market participants, transparent leadership restructuring provides clarity on executive accountability and financial oversight. For business partners and institutional stakeholders, structured continuity within financial controllership ensures stable corporate execution and regulatory compliance across agricultural supply networks.

Key Facts at a Glance

• New CFO Appointment: Amarendra Mohapatra, effective November 1, 2026.

• Outgoing CFO / New MD: Prashant Krishnamurthy steps down as CFO on October 31, 2026, and assumes the role of Managing Director on November 1, 2026.

• Company Identifier: Listed on BSE SME under scrip code 544611 (MAHY.BO).

• Core Sector: Agrochemicals, crop protection, and plant nutrition.

FAQ Section

Who has been appointed as the new CFO of Mahamaya Lifesciences?

Amarendra Mohapatra has been appointed as the new Chief Financial Officer, effective November 1, 2026.

What role is Prashant Krishnamurthy moving into?

Prashant Krishnamurthy is transitioning from his previous role as Executive Director and CFO to become the company's Managing Director, effective November 1, 2026.

When do these executive changes take effect?

Prashant Krishnamurthy steps down as CFO on October 31, 2026, with the new appointments taking formal effect on November 1, 2026.

Where can stakeholders view the official regulatory disclosures for these appointments?

Official announcements and filings can be verified directly on the BSE Limited portal and Mahamaya Lifesciences Official Website.

Source: BSE Limited, Mahamaya Lifesciences Official Portal, Trendlyne Financial Analytics